MDGL

444.83

1.39% 6.10

Handel nachbörslich: 444.83

Madrigal Pharmaceuticals Inc (MDGL)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt MDGL? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$438.73

Offen:

$440.64

24-Stunden-Volumen:

220.73K

Relative Volume:

0.65

Marktkapitalisierung:

$10.10B

Einnahmen:

$958.40M

Nettoeinkommen (Verlust:

$-288.28M

KGV:

-34.58

EPS:

-12.8641

Netto-Cashflow:

$-193.02M

1W Leistung:

+2.77%

1M Leistung:

-4.28%

6M Leistung:

+2.92%

1J Leistung:

+37.71%

1-Tages-Spanne:

$434.30

$448.07

1-Wochen-Bereich:

$418.72

$448.07

52-Wochen-Spanne:

$265.00

$615.00

Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile

Firmenname

Madrigal Pharmaceuticals Inc

Sektor

Healthcare (1118)

Branche

Biotechnology (616)

Telefon

404-380-9263

Adresse

200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA

Mitarbeiter

528

Twitter

@MadrigalPharma

Nächster Verdiensttermin

2024-10-31

Neueste SEC-Einreichungen

MDGL's Discussions on Twitter

Compare MDGL vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
MDGL Madrigal Pharmaceuticals Inc	444.83	9.96B	958.40M	-288.28M	-193.02M	-12.86
VRTX Vertex Pharmaceuticals Inc	469.34	121.46B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	745.77	78.93B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	700.45	43.87B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	313.41	42.07B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	284.05	31.65B	5.36B	287.73M	924.18M	2.5229

Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-28	Eingeleitet	Barclays	Overweight
2026-01-06	Herabstufung	Wolfe Research	Outperform → Peer Perform
2025-11-05	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2025-11-03	Hochstufung	BofA Securities	Underperform → Neutral
2025-10-15	Eingeleitet	Truist	Buy
2025-09-04	Fortgesetzt	H.C. Wainwright	Buy
2025-02-28	Hochstufung	B. Riley Securities	Neutral → Buy
2025-02-27	Bestätigt	H.C. Wainwright	Buy
2024-06-28	Eingeleitet	Cantor Fitzgerald	Neutral
2024-06-11	Eingeleitet	Wolfe Research	Outperform
2024-04-22	Eingeleitet	BofA Securities	Underperform
2024-03-15	Hochstufung	B. Riley Securities	Sell → Neutral
2024-03-06	Eingeleitet	Citigroup	Buy
2024-02-26	Herabstufung	B. Riley Securities	Neutral → Sell
2022-12-20	Bestätigt	Oppenheimer	Outperform
2022-12-19	Bestätigt	H.C. Wainwright	Buy
2022-12-19	Bestätigt	Piper Sandler	Overweight
2022-12-19	Hochstufung	Raymond James	Underperform → Mkt Perform
2022-07-08	Herabstufung	B. Riley Securities	Buy → Neutral
2021-10-07	Eingeleitet	Jefferies	Buy
2021-08-06	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2021-05-20	Fortgesetzt	Goldman	Buy
2020-11-24	Fortgesetzt	Evercore ISI	Outperform
2020-11-06	Bestätigt	H.C. Wainwright	Buy
2020-07-31	Eingeleitet	Piper Sandler	Overweight
2020-06-05	Eingeleitet	BMO Capital Markets	Market Perform
2020-05-05	Eingeleitet	Chardan Capital Markets	Buy
2020-01-30	Eingeleitet	Canaccord Genuity	Buy
2020-01-09	Hochstufung	UBS	Neutral → Buy
2019-11-07	Bestätigt	H.C. Wainwright	Buy
2019-06-25	Eingeleitet	Stifel	Hold
2019-06-10	Hochstufung	B. Riley FBR	Neutral → Buy
2019-02-28	Bestätigt	H.C. Wainwright	Buy
2019-02-22	Eingeleitet	SVB Leerink	Outperform
2019-01-23	Eingeleitet	UBS	Neutral
2018-12-14	Eingeleitet	Wolfe Research	Outperform
2018-12-12	Eingeleitet	B. Riley FBR	Neutral
2018-11-19	Herabstufung	Raymond James	Mkt Perform → Underperform
2018-11-16	Hochstufung	Evercore ISI	In-line → Outperform
2018-09-04	Eingeleitet	Citigroup	Buy
2018-08-06	Herabstufung	Goldman	Buy → Neutral
2018-06-28	Eingeleitet	Raymond James	Mkt Perform

Alle ansehen

Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten

Mar 12, 2026

Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Pullback - simplywall.st

Mar 12, 2026

Barclays PLC Cuts Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

Mar 12, 2026

Mar 11, 2026

Madrigal Pharmaceuticals Grants Equity Awards to 20 New Employees - MyChesCo

Mar 11, 2026

Is Madrigal Pharmaceuticals (MDGL) Pricing Look Interesting After Long Term Share Price Surge? - Yahoo Finance

Mar 11, 2026

Mar 10, 2026

2 Under-the-Radar Stocks to Buy and Hold - The Globe and Mail

Mar 10, 2026

What Makes Madrigal Pharma (MDGL) One of the Shorted Biotech Stocks to Buy - Finviz

Mar 10, 2026

Fieldview Capital Management LLC Invests $2.14 Million in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

Mar 10, 2026

Mar 09, 2026

Discipline and Rules-Based Execution in MDGL Response - Stock Traders Daily

Mar 09, 2026

Mar 08, 2026

Rhenman & Partners Asset Management AB Purchases Shares of 18,250 Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

Mar 08, 2026

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Mar 08, 2026

Mar 07, 2026

Madrigal Pharmaceuticals EVP Dier sells $854k in stock By Investing.com - Investing.com South Africa

Mar 07, 2026

Madrigal Pharmaceuticals EVP Dier sells $854k in stock - Investing.com

Mar 07, 2026

Mar 06, 2026

Pharma News: Why Madrigal Pharmaceuticals Inc. stock could be next big winnerTrade Volume Report & High Accuracy Swing Entry Alerts - Naître et grandir

Mar 06, 2026

Madrigal Pharmaceuticals (NASDAQ:MDGL) CFO Sells $853,984.34 in Stock - MarketBeat

Mar 06, 2026

Madrigal Pharmaceuticals (NASDAQ:MDGL) CEO Sells $718,316.22 in Stock - MarketBeat

Mar 06, 2026

Market Review: Why Madrigal Pharmaceuticals Inc. stock could be next big winnerPortfolio Update Summary & Stock Timing and Entry Methods - Naître et grandir

Mar 06, 2026

Madrigal Pharmaceuticals (NASDAQ:MDGL) General Counsel Sells $155,498.40 in Stock - MarketBeat

Mar 06, 2026

Insider Selling: Madrigal Pharmaceuticals (NASDAQ:MDGL) Director Sells 491 Shares of Stock - MarketBeat

Mar 06, 2026

Madrigal Pharmaceuticals CEO Sibold sells $718k in shares By Investing.com - Investing.com Canada

Mar 06, 2026

Madrigal Pharmaceuticals general counsel sells $155k in stock By Investing.com - Investing.com Canada

Mar 06, 2026

Madrigal Pharmaceuticals CEO Sibold sells $718k in shares - Investing.com

Mar 06, 2026

Madrigal Pharmaceuticals (MDGL) reports record 2025 revenue driven by Rezdiffra success - MSN

Mar 06, 2026

Teachers Retirement System of The State of Kentucky Invests $1.32 Million in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

Mar 06, 2026

Mar 05, 2026

Madrigal gains after Rezdiffra patent win - MSN

Mar 05, 2026

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Mar 05, 2026

20 new Madrigal staff get stock options and 6,882 RSUs at $432 - Stock Titan

Mar 05, 2026

Aug Shorts: Will UnitedHealth Group Incorporated stock go up in YEARQuarterly Performance Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn

Mar 05, 2026

Risk Check: Can Madrigal Pharmaceuticals Inc weather a recessionWeekly Stock Analysis & Safe Entry Momentum Stock Tips - baoquankhu1.vn

Mar 05, 2026

Segall Bryant & Hamill LLC Invests $10.32 Million in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

Mar 05, 2026

A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Weakness - simplywall.st

Mar 05, 2026

Mar 04, 2026

Madrigal Pharmaceuticals: How Noninvasive Data Is Powering a Smarter Clinical Strategy! - Smartkarma

Mar 04, 2026